Hippo pathway-independent restriction of TAZ and YAP by angiomotin - Test2 - elhamkhani - TriplyDB

Hippo pathway-independent restriction of TAZ and YAP by angiomotin

Hippo pathway-independent restriction of TAZ and YAP by angiomotin

http://www.wikidata.org/entity/Q24614424

about

PTPN14 is required for the density-dependent control of YAP1 PTPN14 interacts with and negatively regulates the oncogenic function of YAP A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites Structures of YAP protein domains reveal promising targets for development of new cancer drugs Cadherin signaling: keeping cells in touch Mammalian Hippo signalling: a kinase network regulated by protein-protein interactions From tissue mechanics to transcription factors.The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment Functional role of Mst1/Mst2 in embryonic stem cell differentiation Constitutive expression of Yes-associated protein (Yap) in adult skeletal muscle fibres induces muscle atrophy and myopathy Targeting Mechanotransduction at the Transcriptional Level: YAP and BRD4 Are Novel Therapeutic Targets for the Reversal of Liver Fibrosis Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy YAP and TAZ: a nexus for Hippo signaling and beyond Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer Opposing roles of angiomotin-like-1 and zona occludens-2 on pro-apoptotic function of YAP Tumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap/Taz transcriptional coactivators Regulation of localization and function of the transcriptional co-activator YAP by angiomotin.Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.What do mechanotransduction, Hippo, Wnt, and TGFβ have in common? YAP and TAZ as key orchestrating molecules in ocular health and disease.Pathway databases: making chemical and biological sense of the genomic data flood Angiomotins link F-actin architecture to Hippo pathway signaling.Framework to function: mechanosensitive regulators of gene transcription Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.Angiomotin Family Members: Oncogenes or Tumor Suppressors?CCN1/CYR61: the very model of a modern matricellular protein.Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor.The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis.YAP1 recruits c-Abl to protect angiomotin-like 1 from Nedd4-mediated degradation.Polarity-dependent distribution of angiomotin localizes Hippo signaling in preimplantation embryos.The role of angiomotin phosphorylation in the Hippo pathway during preimplantation mouse development.The hippo pathway in heart development, regeneration, and diseases Angiomotin binding-induced activation of Merlin/NF2 in the Hippo pathway Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing.Deubiquitylating enzyme USP9x regulates hippo pathway activity by controlling angiomotin protein turnover TAZ expression as a prognostic indicator in colorectal cancer.The tyrosine phosphatase PTPN14 is a negative regulator of YAP activity.The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway.Molecular profiling and computational network analysis of TAZ-mediated mammary tumorigenesis identifies actionable therapeutic targets.Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks.Characterization of TAZ domains important for the induction of breast cancer stem cell properties and tumorigenesis.

P2860

Q24297998-AC2036B4-4761-4B4C-B3DE-0DEC5CC217BD Q24316475-9C0D88DB-0DB5-475C-83AC-8C2491C5F917 Q24603988-C3D4DC69-5482-4847-BA37-5009073BDC0D Q24612471-0FB23B29-F54C-4065-9AFE-7511BB7E013F Q26784615-BC2475CE-F701-43AC-AAAB-3611EFEC61BA Q26849472-ABA1889C-AEF5-4B16-8F15-062AED8ED244 Q26866255-24B75741-240B-4104-AC96-4896E4227CB6 Q27025661-94182AF6-B7EA-4976-9D02-C684E98C7967 Q27302367-1B07C754-4DBA-4E26-B08A-616EB03D91AB Q27333208-FA73FE40-40CE-4A73-B4BE-29AE505F9E2E Q28070012-1FBA0707-0E3A-4612-A645-3734A7F9C79D Q28078129-AF7C76FB-A41B-47BE-8A46-6B75D3472DD1 Q28085636-CE930C4B-44DB-4D40-A03A-816D0A2CC1E1 Q28086905-8A89DC1E-3F94-4E39-909D-64F286A8AB58 Q28241192-03DF40BD-B2B4-4AD0-BE7A-D6CCC58CFDEE Q28504464-33766DB0-93FD-4725-BF8A-841FAF06615A Q30352874-12FA0A6B-D320-40D5-8609-E2E1C302C5BC Q30364937-900594F6-0388-43F5-B608-D3B081FEC82E Q30429628-AFF89111-4ED5-4CCF-906E-6960082DCD73 Q30632749-68B23EA6-6640-436E-BB38-E8B944AC96BB Q33604410-E64F261E-EE48-4434-9531-0C4E70CFC3E3 Q33634664-05A2CD65-4D22-40B9-BFC8-CFCC725906DC Q33819083-32EB5517-FC0E-422A-90DE-7A52E6ACA25B Q33837277-DB569BFB-5D4F-49B8-8C57-6605878FC6B5 Q34027926-0F39B140-A7AA-409A-BEA6-509A51AAD3B6 Q34207272-DFD34E36-3AC5-4D0C-BB13-73E7632C47AD Q34246027-E6AA33EE-AD83-489E-8F82-469FCBF88949 Q34256700-CB69A1D9-511D-44F6-B237-F35AF5B23AB8 Q34352631-4391431D-C5E5-441A-988F-30476B983174 Q34420716-06F73C6F-1D85-4236-B4DF-164091F522AC Q34470968-777253FE-321E-4937-8BCD-B71F18138A6D Q34479368-6EFF2BF5-6C6B-4613-9A91-EC47CD916545 Q34480926-FDF70EC9-AEDE-4D21-9CD4-783F35F2CA56 Q34535458-E46D3740-68B7-4E95-BF74-162728A2032F Q34571020-D68712B7-A79A-4F78-B70E-498DFF5B31F9 Q34685404-FB7801A2-C191-4528-A1DB-13782A6ABB2F Q34786592-52EBA8D5-CB24-4E7E-97AB-7D267790AAE8 Q35068051-09C31D96-9069-4846-9CC5-7FA690C23D47 Q35097063-938B85F2-E61A-4767-85FB-761855EDAB4A Q35157451-E257AFEC-30C6-441A-90C3-6E027238C1D2

P2860

Hippo pathway-independent restriction of TAZ and YAP by angiomotin

http://www.wikidata.org/entity/Q24614424

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Hippo pathway-independent restriction of TAZ and YAP by angiomotin

@ast

Hippo pathway-independent restriction of TAZ and YAP by angiomotin

@en

Hippo pathway-independent restriction of TAZ and YAP by angiomotin

@nl

type

label

Hippo pathway-independent restriction of TAZ and YAP by angiomotin

@ast

Hippo pathway-independent restriction of TAZ and YAP by angiomotin

@en

Hippo pathway-independent restriction of TAZ and YAP by angiomotin

@nl

prefLabel

Hippo pathway-independent restriction of TAZ and YAP by angiomotin

@ast

Hippo pathway-independent restriction of TAZ and YAP by angiomotin

@en

Hippo pathway-independent restriction of TAZ and YAP by angiomotin

@nl

P1433

Q24614424-A06C8E58-4FD6-4806-B9C4-15FEC923AF9B

P1476

Q24614424-7880765A-FA31-434E-ADE6-7B83B8A9BF50

P2093

Q24614424-1CE29F4C-CFD7-41DF-9B0C-4B28040C8D8A

Q24614424-24D81964-D211-4D7D-8CF5-46BC4ECB3F7E

Q24614424-67EB853E-AE43-415C-BA71-8DE4A1C03496

Q24614424-8951D1E4-0CE4-401F-8EEA-499838D2E858

Q24614424-90D9A0E0-A791-4DF4-8E1A-08EF7E5FE626

Q24614424-F47953E0-533D-450B-A49D-0C423EE50D87

P2860

Q24614424-12325E73-1F97-4C0C-B99A-6976425B0685

Q24614424-1446FBDB-0867-435B-AA3F-6AE22B79DC94

Q24614424-2A317D4A-1BCE-495D-BF68-B3944835FC32

Q24614424-2B50A31A-6DE4-460F-B917-9E59405FCFD8

Q24614424-39D33496-8568-4C3B-9C05-E99E811D5760

Q24614424-3A44F3CD-03EE-40D0-B782-3936E7316FA3

Q24614424-3E861E8D-FB22-4671-B895-A6DFC089E8BF

Q24614424-4206120C-CDA3-4A21-A491-C5F81FBA80C7

Q24614424-480D0253-4ECD-48CD-A2E6-2441B9DD0032

Q24614424-513F6C68-E297-4D66-A364-4B76E29D2175

P304

Q24614424-507E5F1F-8489-441E-AE4A-2856E7CD2716

P31

Q24614424-8AA69FF7-8949-4431-AF84-EBBC8D0116BA

P3181

Q24614424-6E5818BB-6ED1-42AF-80CA-8B4E4308928E

P356

Q24614424-4BD31E80-1AC8-4E8C-AFEB-98EDFA8C40D0

P407

Q24614424-1C49C021-3294-4769-AB18-CA56CF3B8B40

P433

Q24614424-D1C2A10D-FC80-44B2-B779-4094BED4D5FB

P478

Q24614424-35E650A2-58A7-416A-B578-67B7C4216C82

P577

Q24614424-FDFC3FD9-B8C5-4203-91C8-07B39BB1AA3C

P5875

Q24614424-9E552929-329D-40F4-ABB0-2BF63AAC8778

P698

Q24614424-742109E6-DD21-4144-AEFC-FE1356462DDC

P921

Q24614424-7663FCBE-AC1E-4076-950F-CB6F6A4EA7C9

P932

Q24614424-E8665AC6-2361-4070-937D-2DCBE9BD473F

P3181

P356

JBC.C110.212621

P1433

Journal of Biological Chemistry

P1476

Hippo pathway-independent restriction of TAZ and YAP by angiomotin

@en

P2093

Ajaybabu V Pobbati

http://www.w3.org/2001/XMLSchema#string

Caixia Huang

http://www.w3.org/2001/XMLSchema#string

Chun Jye Lim

http://www.w3.org/2001/XMLSchema#string

Siew Wee Chan

http://www.w3.org/2001/XMLSchema#string

Wanjin Hong

http://www.w3.org/2001/XMLSchema#string

Yaan Fun Chong

http://www.w3.org/2001/XMLSchema#string

P2860

TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins

Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation

A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP)

A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome

Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control

WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ

TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway

Angiomotin regulates endothelial cell-cell junctions and cell motility

TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition

TAZ, a transcriptional modulator of mesenchymal stem cell differentiation

P304

7018-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2015152

http://www.w3.org/2001/XMLSchema#string

P356

10.1074/JBC.C110.212621

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

286

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49745226

http://www.w3.org/2001/XMLSchema#string

P698

21224387

http://www.w3.org/2001/XMLSchema#string

P921

P932

3044958

http://www.w3.org/2001/XMLSchema#string